Trials / Completed
CompletedNCT00705133
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Rajan Saggar · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
Detailed description
Patients with pulmonary hypertension (PH) complicating pulmonary fibrosis are at increased risk of death. There are no therapies proven to be effective in this population, targeting the pulmonary hypertension. The purpose of this study is to evaluate parenteral treprostinil in an open-label fashion in patients with pulmonary fibrosis and an advanced PH phenotype.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treprostinil | For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-01-01
- Completion
- 2011-04-01
- First posted
- 2008-06-25
- Last updated
- 2020-09-09
- Results posted
- 2020-09-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00705133. Inclusion in this directory is not an endorsement.